Mon Nov 11 22:08:24 UTC 2024: ## M&G PLC Invests in Intra-Cellular Therapies, Joining a Growing List of Institutional Investors

**Sioux Falls, SD** – M&G PLC, a prominent investment firm, has acquired a new stake in Intra-Cellular Therapies, Inc. (NASDAQ: ITCI), a biopharmaceutical company specializing in neurological and neuropsychiatric disorder treatments. This move, revealed in the firm’s latest 13F filing with the Securities and Exchange Commission (SEC), sees M&G PLC owning 124,324 shares of Intra-Cellular Therapies stock, valued at approximately $9,076,000.

M&G PLC’s investment in Intra-Cellular Therapies joins a recent trend of institutional investors increasing their positions in the company. Emerald Advisers LLC, Harbor Capital Advisors Inc., Emerald Mutual Fund Advisers Trust, and US Bancorp DE have all raised their stakes in the company during the third quarter. This collective interest from institutions highlights the growing confidence in Intra-Cellular Therapies’ potential.

Research analysts are also optimistic about Intra-Cellular Therapies’ future, with eleven analysts issuing a “buy” rating and two assigning a “hold” rating. The consensus rating on the stock is “Moderate Buy” with a price target of $97.23.

Despite missing earnings estimates for the third quarter, Intra-Cellular Therapies saw a 39% year-over-year revenue increase, signaling a promising growth trajectory. The company’s focus on developing treatments for significant medical needs, coupled with positive analyst assessments, suggests continued potential for future success.

While Intra-Cellular Therapies may not be among the top five stocks recommended by MarketBeat’s top-rated analysts, the company’s overall performance and institutional interest suggest it remains a valuable investment prospect for those seeking exposure to the growing biopharmaceutical sector.

Read More